Skip to main content
Top
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Review

Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact

Authors: Anna Linda Zignego, Carlo Giannini, Laura Gragnani, Alessia Piluso, Elisa Fognani

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

The relationship between Hepatitis C Virus (HCV) infection and immunosuppression is complex and multifaceted. Although HCV-related hepatocytolysis is classically interpreted as secondary to the attack by cytotoxic T lymphocytes against infected cells, the liver disease is usually exacerbated and more rapidly evolutive in immunosuppressed patients. This generally occurs during the immunosuppression state, and not at the reconstitution of the host response after immunosuppressive therapy discontinuation. The field of immunosuppression and HCV infection is complicated both by the different outcome observed in different situations and/or by contrasting data obtained in the same conditions, with several still unanswered questions, such as the opportunity to modify treatment schedules in the setting of post-transplant follow-up. The complexity of this field is further complicated by the intrinsic tendency of HCV infection in itself to lead to disorders of the immune system. This review will briefly outline the current knowledge about the pathogenesis of both hepatic and extrahepatic HCV-related disorders and the principal available data concerning HCV infection in a condition of impairment of the immune system. Attention will be especially focused on some conditions - liver or kidney transplantation, the use of biologic drugs and cancer chemotherapy - for which more abundant and interesting data exist.
Literature
1.
go back to reference Einav S, Koziel MJ: Immunopathogenesis of hepatitis C virus in the immunosuppressed host. Transpl Infect Dis. 2002, 4: 85-92. 10.1034/j.1399-3062.2002.t01-2-02001.x.PubMed Einav S, Koziel MJ: Immunopathogenesis of hepatitis C virus in the immunosuppressed host. Transpl Infect Dis. 2002, 4: 85-92. 10.1034/j.1399-3062.2002.t01-2-02001.x.PubMed
2.
go back to reference Cheney CP, Chopra S, Graham C: Hepatitis C. Infect Dis Clin North Am. 2000, 14: 633-667. 10.1016/S0891-5520(05)70125-2.PubMed Cheney CP, Chopra S, Graham C: Hepatitis C. Infect Dis Clin North Am. 2000, 14: 633-667. 10.1016/S0891-5520(05)70125-2.PubMed
3.
go back to reference Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997, 349: 825-832. 10.1016/S0140-6736(96)07642-8.PubMed Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997, 349: 825-832. 10.1016/S0140-6736(96)07642-8.PubMed
4.
go back to reference Ermis F, Akyuz F, Demir K, Besisik F, Boztas G, Mungan Z: Rapidly progressive HCV cirrhosis in a hypogammaglobulinemic patient. Intern Med. 2008, 47: 415-417. 10.2169/internalmedicine.47.0535.PubMed Ermis F, Akyuz F, Demir K, Besisik F, Boztas G, Mungan Z: Rapidly progressive HCV cirrhosis in a hypogammaglobulinemic patient. Intern Med. 2008, 47: 415-417. 10.2169/internalmedicine.47.0535.PubMed
5.
go back to reference Bjoro K, Skaug K, Haaland T, Froland SS: Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM. 1999, 92: 433-441. 10.1093/qjmed/92.8.433.PubMed Bjoro K, Skaug K, Haaland T, Froland SS: Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM. 1999, 92: 433-441. 10.1093/qjmed/92.8.433.PubMed
6.
go back to reference Bjorkander J, Cunningham-Rundles C, Lundin P, Olsson R, Soderstrom R, Hanson LA: Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med. 1988, 84: 107-111. 10.1016/0002-9343(88)90016-2.PubMed Bjorkander J, Cunningham-Rundles C, Lundin P, Olsson R, Soderstrom R, Hanson LA: Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med. 1988, 84: 107-111. 10.1016/0002-9343(88)90016-2.PubMed
7.
go back to reference Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999, 30: 1054-1058. 10.1002/hep.510300409.PubMed Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999, 30: 1054-1058. 10.1002/hep.510300409.PubMed
8.
go back to reference Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodriguez M, Sales Gilabert M: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997, 26: 1-5.PubMed Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodriguez M, Sales Gilabert M: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997, 26: 1-5.PubMed
9.
go back to reference Roe B, Hall WW: Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev Mol Med. 2008, 10: e30-PubMed Roe B, Hall WW: Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev Mol Med. 2008, 10: e30-PubMed
10.
go back to reference Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells–a mechanism of immune evasion?. Nat Med. 1996, 2: 1361-1366. 10.1038/nm1296-1361.PubMed Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells–a mechanism of immune evasion?. Nat Med. 1996, 2: 1361-1366. 10.1038/nm1296-1361.PubMed
11.
go back to reference Ivantes CA, Amarante H, Ioshii SO, Pasquini R: Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant. 2004, 33: 1181-1185. 10.1038/sj.bmt.1704519.PubMed Ivantes CA, Amarante H, Ioshii SO, Pasquini R: Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant. 2004, 33: 1181-1185. 10.1038/sj.bmt.1704519.PubMed
12.
go back to reference Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R: Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996, 334: 815-820. 10.1056/NEJM199603283341302.PubMed Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R: Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996, 334: 815-820. 10.1056/NEJM199603283341302.PubMed
13.
go back to reference Price DA, Klenerman P, Booth BL, Phillips RE, Sewell AK: Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunol Today. 1999, 20: 212-216. 10.1016/S0167-5699(99)01447-4.PubMed Price DA, Klenerman P, Booth BL, Phillips RE, Sewell AK: Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunol Today. 1999, 20: 212-216. 10.1016/S0167-5699(99)01447-4.PubMed
14.
go back to reference Andres A, Gerstel E, Combescure C, Asthana S, Merani S, Majno P, Berney T, Morel P, Kneteman N, Mentha G, Toso C: A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis. Transplantation. 2012, 93: 717-722. 10.1097/TP.0b013e318246f8b3.PubMed Andres A, Gerstel E, Combescure C, Asthana S, Merani S, Majno P, Berney T, Morel P, Kneteman N, Mentha G, Toso C: A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis. Transplantation. 2012, 93: 717-722. 10.1097/TP.0b013e318246f8b3.PubMed
15.
go back to reference Koziel MJ: Influence of HIV co-infection on hepatitis C immunopathogenesis. J Hepatol. 2006, 44: S14-18.PubMed Koziel MJ: Influence of HIV co-infection on hepatitis C immunopathogenesis. J Hepatol. 2006, 44: S14-18.PubMed
16.
go back to reference Craxi A, Laffi G, Zignego AL: Hepatitis C virus (HCV) infection: A systemic disease. Mol Aspects Med. 2008, 29: 85-95. 10.1016/j.mam.2007.09.017.PubMed Craxi A, Laffi G, Zignego AL: Hepatitis C virus (HCV) infection: A systemic disease. Mol Aspects Med. 2008, 29: 85-95. 10.1016/j.mam.2007.09.017.PubMed
17.
go back to reference Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med. 2001, 345: 41-52. 10.1056/NEJM200107053450107.PubMed Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med. 2001, 345: 41-52. 10.1056/NEJM200107053450107.PubMed
18.
go back to reference Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006, 1: 23-61. 10.1146/annurev.pathol.1.110304.100230.PubMed Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006, 1: 23-61. 10.1146/annurev.pathol.1.110304.100230.PubMed
19.
go back to reference Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999, 17: 189-220. 10.1146/annurev.immunol.17.1.189.PubMed Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999, 17: 189-220. 10.1146/annurev.immunol.17.1.189.PubMed
20.
go back to reference Ahmad A, Alvarez F: Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J Leukoc Biol. 2004, 76: 743-759. 10.1189/jlb.0304197.PubMed Ahmad A, Alvarez F: Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J Leukoc Biol. 2004, 76: 743-759. 10.1189/jlb.0304197.PubMed
21.
go back to reference Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F: Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002, 195: 35-41. 10.1084/jem.20011124.PubMedPubMedCentral Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F: Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002, 195: 35-41. 10.1084/jem.20011124.PubMedPubMedCentral
22.
go back to reference Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B: Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002, 169: 3447-3458.PubMed Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B: Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002, 169: 3447-3458.PubMed
23.
go back to reference Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, Pape GR: Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995, 346: 1006-1007. 10.1016/S0140-6736(95)91691-1.PubMed Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, Pape GR: Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995, 346: 1006-1007. 10.1016/S0140-6736(95)91691-1.PubMed
24.
go back to reference Rehermann B: Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009, 119: 1745-1754. 10.1172/JCI39133.PubMedPubMedCentral Rehermann B: Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009, 119: 1745-1754. 10.1172/JCI39133.PubMedPubMedCentral
25.
go back to reference Shoukry NH, Cawthon AG, Walker CM: Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol. 2004, 58: 391-424. 10.1146/annurev.micro.58.030603.123836.PubMed Shoukry NH, Cawthon AG, Walker CM: Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol. 2004, 58: 391-424. 10.1146/annurev.micro.58.030603.123836.PubMed
26.
go back to reference Kanto T, Hayashi N: Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med. 2006, 45: 183-191. 10.2169/internalmedicine.45.1530.PubMed Kanto T, Hayashi N: Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med. 2006, 45: 183-191. 10.2169/internalmedicine.45.1530.PubMed
27.
go back to reference Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, Fusamoto H, Kamada T: Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun. 1994, 204: 468-474. 10.1006/bbrc.1994.2483.PubMed Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, Fusamoto H, Kamada T: Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun. 1994, 204: 468-474. 10.1006/bbrc.1994.2483.PubMed
28.
go back to reference Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T: Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 1994, 19: 1354-1359. 10.1002/hep.1840190606.PubMed Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T: Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 1994, 19: 1354-1359. 10.1002/hep.1840190606.PubMed
29.
go back to reference Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001, 194: 1395-1406. 10.1084/jem.194.10.1395.PubMedPubMedCentral Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001, 194: 1395-1406. 10.1084/jem.194.10.1395.PubMedPubMedCentral
30.
go back to reference Bantel H, Lugering A, Poremba C, Lugering N, Held J, Domschke W, Schulze-Osthoff K: Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology. 2001, 34: 758-767. 10.1053/jhep.2001.28229.PubMed Bantel H, Lugering A, Poremba C, Lugering N, Held J, Domschke W, Schulze-Osthoff K: Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology. 2001, 34: 758-767. 10.1053/jhep.2001.28229.PubMed
31.
go back to reference Bertoletti A, Maini MK: Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Curr Opin Immunol. 2000, 12: 403-408. 10.1016/S0952-7915(00)00108-4.PubMed Bertoletti A, Maini MK: Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Curr Opin Immunol. 2000, 12: 403-408. 10.1016/S0952-7915(00)00108-4.PubMed
32.
go back to reference Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000, 191: 1269-1280. 10.1084/jem.191.8.1269.PubMedPubMedCentral Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000, 191: 1269-1280. 10.1084/jem.191.8.1269.PubMedPubMedCentral
33.
go back to reference Gremion C, Cerny A: Hepatitis C virus and the immune system: a concise review. Rev Med Virol. 2005, 15: 235-268. 10.1002/rmv.466.PubMed Gremion C, Cerny A: Hepatitis C virus and the immune system: a concise review. Rev Med Virol. 2005, 15: 235-268. 10.1002/rmv.466.PubMed
34.
go back to reference Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Chung RT, Walker BD: Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002, 76: 12584-12595. 10.1128/JVI.76.24.12584-12595.2002.PubMedPubMedCentral Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Chung RT, Walker BD: Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002, 76: 12584-12595. 10.1128/JVI.76.24.12584-12595.2002.PubMedPubMedCentral
35.
go back to reference Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, Bouwer HG, Hinrichs DJ: Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002, 35: 190-198. 10.1053/jhep.2002.30293.PubMed Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, Bouwer HG, Hinrichs DJ: Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002, 35: 190-198. 10.1053/jhep.2002.30293.PubMed
36.
go back to reference Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N: Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992, 258: 135-140. 10.1126/science.1279801.PubMed Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N: Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992, 258: 135-140. 10.1126/science.1279801.PubMed
37.
go back to reference Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P: Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet. 1994, 343: 388-390. 10.1016/S0140-6736(94)91224-6.PubMed Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P: Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet. 1994, 343: 388-390. 10.1016/S0140-6736(94)91224-6.PubMed
38.
go back to reference Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, Haber PS, Marinos G, Levy MH, Kaldor JM: Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis. 2004, 189: 1846-1855. 10.1086/383279.PubMed Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, Haber PS, Marinos G, Levy MH, Kaldor JM: Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis. 2004, 189: 1846-1855. 10.1086/383279.PubMed
39.
go back to reference Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH: Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996, 93: 15394-15399. 10.1073/pnas.93.26.15394.PubMedPubMedCentral Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH: Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996, 93: 15394-15399. 10.1073/pnas.93.26.15394.PubMedPubMedCentral
40.
go back to reference Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P: Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010, 116: 335-342. 10.1182/blood-2009-11-253948.PubMed Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P: Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010, 116: 335-342. 10.1182/blood-2009-11-253948.PubMed
41.
go back to reference Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB: Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis. 2007, 39: 2-17. 10.1016/j.dld.2006.06.008.PubMed Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB: Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis. 2007, 39: 2-17. 10.1016/j.dld.2006.06.008.PubMed
42.
go back to reference Choi J: Ou JH: Mechanisms of liver injury III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 2006, 290: G847-851.PubMed Choi J: Ou JH: Mechanisms of liver injury III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 2006, 290: G847-851.PubMed
43.
go back to reference Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, McLauchlan J: Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic. 2008, 9: 1268-1282. 10.1111/j.1600-0854.2008.00767.x.PubMed Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, McLauchlan J: Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic. 2008, 9: 1268-1282. 10.1111/j.1600-0854.2008.00767.x.PubMed
44.
go back to reference Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000, 33: 106-115. 10.1016/S0168-8278(00)80166-X.PubMed Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000, 33: 106-115. 10.1016/S0168-8278(00)80166-X.PubMed
45.
go back to reference Giannini C, Brechot C: Hepatitis C virus biology. Cell Death Differ. 2003, 10 (Suppl 1): S27-38.PubMed Giannini C, Brechot C: Hepatitis C virus biology. Cell Death Differ. 2003, 10 (Suppl 1): S27-38.PubMed
46.
go back to reference Zignego AL, Macchia D, Monti M, Thiers V, Mazzetti M, Foschi M, Maggi E, Romagnani S, Gentilini P, Brechot C: Infection of peripheral mononuclear blood cells by hepatitis C virus [see comments]. J Hepatol. 1992, 15: 382-386.PubMed Zignego AL, Macchia D, Monti M, Thiers V, Mazzetti M, Foschi M, Maggi E, Romagnani S, Gentilini P, Brechot C: Infection of peripheral mononuclear blood cells by hepatitis C virus [see comments]. J Hepatol. 1992, 15: 382-386.PubMed
47.
go back to reference Zignego AL, Giannini C, Monti M, Gragnani L: Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis. 2007, 39 (Suppl 1): S38-45.PubMed Zignego AL, Giannini C, Monti M, Gragnani L: Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis. 2007, 39 (Suppl 1): S38-45.PubMed
48.
go back to reference Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, Liberati AM, Gerli R, Greco F, Moretti A: Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 1993, 81: 1132-1136.PubMed Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, Liberati AM, Gerli R, Greco F, Moretti A: Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 1993, 81: 1132-1136.PubMed
49.
go back to reference Ferri C, Monti M, La Civita L, Longombardo G, Greco F, Pasero G, Gentilini P, Bombardieri S, Zignego AL: Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood. 1993, 82: 3701-3704.PubMed Ferri C, Monti M, La Civita L, Longombardo G, Greco F, Pasero G, Gentilini P, Bombardieri S, Zignego AL: Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood. 1993, 82: 3701-3704.PubMed
50.
go back to reference Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, Lombardini F, Greco F, Capochiani E, Mazzoni A: Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol. 1994, 88: 392-394. 10.1111/j.1365-2141.1994.tb05036.x.PubMed Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, Lombardini F, Greco F, Capochiani E, Mazzoni A: Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol. 1994, 88: 392-394. 10.1111/j.1365-2141.1994.tb05036.x.PubMed
51.
go back to reference Ferri C, La Civita L, Caracciolo F, Zignego AL: Non-Hodgkin's lymphoma: possible role of hepatitis C virus [letter]. Jama. 1994, 272: 355-356.PubMed Ferri C, La Civita L, Caracciolo F, Zignego AL: Non-Hodgkin's lymphoma: possible role of hepatitis C virus [letter]. Jama. 1994, 272: 355-356.PubMed
52.
go back to reference Ferri C, La Civita L, Monti M, Longombardo G, Greco F, Pasero G, Zignego AL: Can type C hepatitis infection be complicated by malignant lymphoma? [letter; comment]. Lancet. 1995, 346: 1426-1427.PubMed Ferri C, La Civita L, Monti M, Longombardo G, Greco F, Pasero G, Zignego AL: Can type C hepatitis infection be complicated by malignant lymphoma? [letter; comment]. Lancet. 1995, 346: 1426-1427.PubMed
53.
go back to reference La Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, Ferri C: Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum. 1995, 38: 1859-1860. 10.1002/art.1780381222.PubMed La Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, Ferri C: Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum. 1995, 38: 1859-1860. 10.1002/art.1780381222.PubMed
54.
go back to reference Zignego AL, Ferri C, Monti M, LaCivita L, Giannini C, Careccia G, Giannelli F, Pasero G, Bombardieri S, Gentilini P: Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin Exp Rheumatol. 1995, 13: S33-37.PubMed Zignego AL, Ferri C, Monti M, LaCivita L, Giannini C, Careccia G, Giannelli F, Pasero G, Bombardieri S, Gentilini P: Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin Exp Rheumatol. 1995, 13: S33-37.PubMed
55.
go back to reference Zignego AL, Ferri C, Giannini C, Monti M, La Civita L, Careccia G, Longombardo G, Lombardini F, Bombardieri S, Gentilini P: Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med. 1996, 124: 31-34.PubMed Zignego AL, Ferri C, Giannini C, Monti M, La Civita L, Careccia G, Longombardo G, Lombardini F, Bombardieri S, Gentilini P: Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med. 1996, 124: 31-34.PubMed
56.
go back to reference Ferri C, La Civita L, Zignego AL, Pasero G: Hepatitis-C-virus infection and cancer [letter]. Int J Cancer. 1997, 71: 1113-1115. 10.1002/(SICI)1097-0215(19970611)71:6<1113::AID-IJC31>3.0.CO;2-B.PubMed Ferri C, La Civita L, Zignego AL, Pasero G: Hepatitis-C-virus infection and cancer [letter]. Int J Cancer. 1997, 71: 1113-1115. 10.1002/(SICI)1097-0215(19970611)71:6<1113::AID-IJC31>3.0.CO;2-B.PubMed
57.
go back to reference Ferri C, Lo Jacono F, Monti M, Caracciolo F, La Civita L, Barsanti LA, Longombardo G, Lombardini F, Careccia G, Zignego AL: Lymphotropic virus infection of peripheral blood mononuclear cells in B- cell non-Hodgkin's lymphoma. Acta Haematol. 1997, 98: 89-94. 10.1159/000203597.PubMed Ferri C, Lo Jacono F, Monti M, Caracciolo F, La Civita L, Barsanti LA, Longombardo G, Lombardini F, Careccia G, Zignego AL: Lymphotropic virus infection of peripheral blood mononuclear cells in B- cell non-Hodgkin's lymphoma. Acta Haematol. 1997, 98: 89-94. 10.1159/000203597.PubMed
58.
go back to reference Zignego AL, Ferri C, Giannini C, La Civita L, Careccia G, Longombardo G, Bellesi G, Caracciolo F, Thiers V, Gentilini P: Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non- Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol. 1997, 142: 545-555. 10.1007/s007050050100.PubMed Zignego AL, Ferri C, Giannini C, La Civita L, Careccia G, Longombardo G, Bellesi G, Caracciolo F, Thiers V, Gentilini P: Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non- Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol. 1997, 142: 545-555. 10.1007/s007050050100.PubMed
59.
go back to reference Zignego AL, Ferri C, Innocenti F, Giannini C, Monti M, Bellesi G, Gentilini P: Lack of preferential localization of tumoral mass in B-cell non- Hodgkin's lymphoma associated with hepatitis C virus infection [letter]. Blood. 1997, 89: 3066-3068.PubMed Zignego AL, Ferri C, Innocenti F, Giannini C, Monti M, Bellesi G, Gentilini P: Lack of preferential localization of tumoral mass in B-cell non- Hodgkin's lymphoma associated with hepatitis C virus infection [letter]. Blood. 1997, 89: 3066-3068.PubMed
60.
go back to reference Zignego AL, Giannini C, Ferri C: Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol. 2007, 13: 2467-2478.PubMedPubMedCentral Zignego AL, Giannini C, Ferri C: Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol. 2007, 13: 2467-2478.PubMedPubMedCentral
61.
go back to reference Andreone P, Zignego AL, Cursaro C, Gramenzi A, Gherlinzoni F, Fiorino S, Giannini C, Boni P, Sabattini E, Pileri S: Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med. 1998, 129: 294-298.PubMed Andreone P, Zignego AL, Cursaro C, Gramenzi A, Gherlinzoni F, Fiorino S, Giannini C, Boni P, Sabattini E, Pileri S: Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med. 1998, 129: 294-298.PubMed
62.
go back to reference Ferri C, Pileri S, Zignego AL: Hepatitis C virus infection and non-Hodgkin's lymphoma. Infectious causes of cancer Targets for intervention. Edited by: Geodert J. 2000, The Human Press inc, (NIH) NCI. Totowa, New Jersey, 349-368. Ferri C, Pileri S, Zignego AL: Hepatitis C virus infection and non-Hodgkin's lymphoma. Infectious causes of cancer Targets for intervention. Edited by: Geodert J. 2000, The Human Press inc, (NIH) NCI. Totowa, New Jersey, 349-368.
63.
go back to reference Ferri C, Caracciolo F, La Civita L, Monti M, Longombardo G, Greco F, Zignego AL: Hepatitis C virus infection and B-cell lymphomas [letter]. Eur J Cancer. 1994, 10: 1591-1592. Ferri C, Caracciolo F, La Civita L, Monti M, Longombardo G, Greco F, Zignego AL: Hepatitis C virus infection and B-cell lymphomas [letter]. Eur J Cancer. 1994, 10: 1591-1592.
64.
go back to reference Ferri C, La Civita L, Monti M, Giannini C, Cecchetti R, Caracciolo F, Longombardo G, Lombardini F, Zignego AL: Chronic hepatitis C and B-cell non-Hodgkin's lymphoma. Qjm. 1996, 89: 117-122. 10.1093/qjmed/89.2.117.PubMed Ferri C, La Civita L, Monti M, Giannini C, Cecchetti R, Caracciolo F, Longombardo G, Lombardini F, Zignego AL: Chronic hepatitis C and B-cell non-Hodgkin's lymphoma. Qjm. 1996, 89: 117-122. 10.1093/qjmed/89.2.117.PubMed
65.
go back to reference Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG, Iannitto E, De Renzo A, Martino B, Liso V: Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case–control study. Blood. 2003, 102: 996-999. 10.1182/blood-2002-10-3230.PubMed Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG, Iannitto E, De Renzo A, Martino B, Liso V: Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case–control study. Blood. 2003, 102: 996-999. 10.1182/blood-2002-10-3230.PubMed
66.
go back to reference Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002, 347: 89-94. 10.1056/NEJMoa013376.PubMed Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002, 347: 89-94. 10.1056/NEJMoa013376.PubMed
67.
go back to reference Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Kumada H: Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007, 120: 1034-1041. 10.1016/j.amjmed.2007.06.022.PubMed Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Kumada H: Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007, 120: 1034-1041. 10.1016/j.amjmed.2007.06.022.PubMed
68.
go back to reference de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S: Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008, 6: 451-458. 10.1016/j.cgh.2008.02.011.PubMedPubMedCentral de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S: Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008, 6: 451-458. 10.1016/j.cgh.2008.02.011.PubMedPubMedCentral
69.
go back to reference Gournay J, Ferrell LD, Roberts JP, Ascher NL, Wright TL, Lake JR: Cryoglobulinemia presenting after liver transplantation. Gastroenterology. 1996, 110: 265-270. 10.1053/gast.1996.v110.pm8536866.PubMed Gournay J, Ferrell LD, Roberts JP, Ascher NL, Wright TL, Lake JR: Cryoglobulinemia presenting after liver transplantation. Gastroenterology. 1996, 110: 265-270. 10.1053/gast.1996.v110.pm8536866.PubMed
70.
go back to reference McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, Jevnikar AM, Rizkalla KS: Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl. 2000, 6: 570-574. 10.1053/jlts.2000.7578.PubMed McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, Jevnikar AM, Rizkalla KS: Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl. 2000, 6: 570-574. 10.1053/jlts.2000.7578.PubMed
71.
go back to reference Zignego AL, Gragnani L, Di Pietro E, Solazzo V, Puliti S, Laffi G, Gentilini P: HCV infection, malignancy, and liver transplantation. Transplant Proc. 2003, 35: 1032-1033. 10.1016/S0041-1345(03)00257-4.PubMed Zignego AL, Gragnani L, Di Pietro E, Solazzo V, Puliti S, Laffi G, Gentilini P: HCV infection, malignancy, and liver transplantation. Transplant Proc. 2003, 35: 1032-1033. 10.1016/S0041-1345(03)00257-4.PubMed
72.
go back to reference Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, Efremov DG: Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood. 1998, 91: 2433-2442.PubMed Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, Efremov DG: Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood. 1998, 91: 2433-2442.PubMed
73.
go back to reference De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A, Boiocchi M: Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000, 96: 3578-3584.PubMed De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A, Boiocchi M: Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000, 96: 3578-3584.PubMed
74.
go back to reference Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S: Binding of hepatitis C virus to CD81. Science. 1998, 282: 938-941.PubMed Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S: Binding of hepatitis C virus to CD81. Science. 1998, 282: 938-941.PubMed
75.
go back to reference Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G, Abrignani S: Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A. 2005, 102: 18544-18549. 10.1073/pnas.0509402102.PubMedPubMedCentral Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G, Abrignani S: Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A. 2005, 102: 18544-18549. 10.1073/pnas.0509402102.PubMedPubMedCentral
76.
go back to reference Chan CH, Hadlock KG, Foung SK, Levy S: V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood. 2001, 97: 1023-1026. 10.1182/blood.V97.4.1023.PubMed Chan CH, Hadlock KG, Foung SK, Levy S: V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood. 2001, 97: 1023-1026. 10.1182/blood.V97.4.1023.PubMed
77.
go back to reference Carbonari M, Caprini E, Tedesco T, Mazzetta F, Tocco V, Casato M, Russo G, Fiorilli M: Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol. 2005, 174: 6532-6539.PubMed Carbonari M, Caprini E, Tedesco T, Mazzetta F, Tocco V, Casato M, Russo G, Fiorilli M: Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol. 2005, 174: 6532-6539.PubMed
78.
go back to reference Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, Jacobson IM, Rice CM, Dustin LB: Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011, 117: 5425-5437. 10.1182/blood-2010-10-312942.PubMedPubMedCentral Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, Jacobson IM, Rice CM, Dustin LB: Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011, 117: 5425-5437. 10.1182/blood-2010-10-312942.PubMedPubMedCentral
79.
go back to reference Visentini M, Cagliuso M, Conti V, Carbonari M, Casato M, Fiorilli M: The V(H)1-69-expressing marginal zone B cells expanded in HCV-associated mixed cryoglobulinemia display proliferative anergy irrespective of CD21(low) phenotype. Blood. 2011, 118: 3440-3441. 10.1182/blood-2011-05-353821. author reply 3442PubMed Visentini M, Cagliuso M, Conti V, Carbonari M, Casato M, Fiorilli M: The V(H)1-69-expressing marginal zone B cells expanded in HCV-associated mixed cryoglobulinemia display proliferative anergy irrespective of CD21(low) phenotype. Blood. 2011, 118: 3440-3441. 10.1182/blood-2011-05-353821. author reply 3442PubMed
80.
go back to reference Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA, Mazzarino MC: Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. Cancer Biol Ther. 2005, 4: 1192-1194. 10.4161/cbt.4.11.2087.PubMed Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA, Mazzarino MC: Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. Cancer Biol Ther. 2005, 4: 1192-1194. 10.4161/cbt.4.11.2087.PubMed
81.
go back to reference Libra M, Mangano K, Anzaldi M, Quattrocchi C, Donia M, di Marco R, Signorelli S, Scalia G, Zignego AL, de Re V: Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol Rep. 2006, 15: 1305-1308.PubMed Libra M, Mangano K, Anzaldi M, Quattrocchi C, Donia M, di Marco R, Signorelli S, Scalia G, Zignego AL, de Re V: Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol Rep. 2006, 15: 1305-1308.PubMed
82.
go back to reference Antonelli A, Ferri C, Ferrari SM, Ruffilli I, Colaci M, Frascerra S, Miccoli M, Franzoni F, Galetta F, Fallahi P: High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon-{gamma}. J Rheumatol. 2011, 38: 1947-1952. 10.3899/jrheum.110133.PubMed Antonelli A, Ferri C, Ferrari SM, Ruffilli I, Colaci M, Frascerra S, Miccoli M, Franzoni F, Galetta F, Fallahi P: High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon-{gamma}. J Rheumatol. 2011, 38: 1947-1952. 10.3899/jrheum.110133.PubMed
83.
go back to reference De Vita S, Quartuccio L, Fabris M: Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?. Autoimmun Rev. 2008, 8: 95-99. 10.1016/j.autrev.2008.05.005.PubMed De Vita S, Quartuccio L, Fabris M: Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?. Autoimmun Rev. 2008, 8: 95-99. 10.1016/j.autrev.2008.05.005.PubMed
84.
go back to reference Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, Monti M, Petrarca A, Ranieri J, Razzolini G, Froio V: Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum. 2011, 63: 1446-1451. 10.1002/art.30274.PubMed Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, Monti M, Petrarca A, Ranieri J, Razzolini G, Froio V: Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum. 2011, 63: 1446-1451. 10.1002/art.30274.PubMed
85.
go back to reference Bronowicki JP, Loriot MA, Thiers V, Grignon Y, Zignego AL, Brechot C: Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology. 1998, 28: 211-218.PubMed Bronowicki JP, Loriot MA, Thiers V, Grignon Y, Zignego AL, Brechot C: Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology. 1998, 28: 211-218.PubMed
86.
go back to reference Sung VM, Shimodaira S, Doughty AL, Picchio GR, Can H, Yen TS, Lindsay KL, Levine AM, Lai MM: Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol. 2003, 77: 2134-2146. 10.1128/JVI.77.3.2134-2146.2003.PubMedPubMedCentral Sung VM, Shimodaira S, Doughty AL, Picchio GR, Can H, Yen TS, Lindsay KL, Levine AM, Lai MM: Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol. 2003, 77: 2134-2146. 10.1128/JVI.77.3.2134-2146.2003.PubMedPubMedCentral
87.
go back to reference Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, Lai MY, Lai MM: Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A. 2004, 101: 4262-4267. 10.1073/pnas.0303971101.PubMedPubMedCentral Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, Lai MY, Lai MM: Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A. 2004, 101: 4262-4267. 10.1073/pnas.0303971101.PubMedPubMedCentral
88.
go back to reference Ito M, Murakami K, Suzuki T, Mochida K, Suzuki M, Ikebuchi K, Yamaguchi K, Mizuochi T: Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol. 2010, 135: 459-465. 10.1016/j.clim.2010.02.002.PubMed Ito M, Murakami K, Suzuki T, Mochida K, Suzuki M, Ikebuchi K, Yamaguchi K, Mizuochi T: Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol. 2010, 135: 459-465. 10.1016/j.clim.2010.02.002.PubMed
89.
go back to reference Ishikawa T, Shibuya K, Yasui K, Mitamura K, Ueda S: Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp Immunol Microbiol Infect Dis. 2003, 26: 115-124. 10.1016/S0147-9571(02)00038-3.PubMed Ishikawa T, Shibuya K, Yasui K, Mitamura K, Ueda S: Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp Immunol Microbiol Infect Dis. 2003, 26: 115-124. 10.1016/S0147-9571(02)00038-3.PubMed
90.
go back to reference Machida K, Tsukiyama-Kohara K, Sekiguch S, Seike E, Tone S, Hayashi Y, Tobita Y, Kasama Y, Shimizu M, Takahashi H: Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology. 2009, 137: 285-296. 10.1053/j.gastro.2009.03.061.PubMedPubMedCentral Machida K, Tsukiyama-Kohara K, Sekiguch S, Seike E, Tone S, Hayashi Y, Tobita Y, Kasama Y, Shimizu M, Takahashi H: Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology. 2009, 137: 285-296. 10.1053/j.gastro.2009.03.061.PubMedPubMedCentral
91.
go back to reference Kasama Y, Sekiguchi S, Saito M, Tanaka K, Satoh M, Kuwahara K, Sakaguchi N, Takeya M, Hiasa Y, Kohara M, Tsukiyama-Kohara K: Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood. 2010, 116: 4926-4933. 10.1182/blood-2010-05-283358.PubMedPubMedCentral Kasama Y, Sekiguchi S, Saito M, Tanaka K, Satoh M, Kuwahara K, Sakaguchi N, Takeya M, Hiasa Y, Kohara M, Tsukiyama-Kohara K: Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood. 2010, 116: 4926-4933. 10.1182/blood-2010-05-283358.PubMedPubMedCentral
92.
go back to reference Alisi A, Giannini C, Spaziani A, Caini P, Zignego AL, Balsano C: Involvement of PI3K in HCV-related lymphoproliferative disorders. J Cell Physiol. 2008, 214: 396-404. 10.1002/jcp.21211.PubMed Alisi A, Giannini C, Spaziani A, Caini P, Zignego AL, Balsano C: Involvement of PI3K in HCV-related lymphoproliferative disorders. J Cell Physiol. 2008, 214: 396-404. 10.1002/jcp.21211.PubMed
93.
go back to reference Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, Marrocchi EM, Di Pietro E, La Villa G, Laffi G, Gentilini P: Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med. 2002, 137: 571-580.PubMed Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, Marrocchi EM, Di Pietro E, La Villa G, Laffi G, Gentilini P: Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med. 2002, 137: 571-580.PubMed
94.
go back to reference Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, Giannini C, Monti M, Caini P, Villa GL, Laffi G, Gentilini P: T(14;18) translocation in chronic hepatitis C virus infection. Hepatology. 2000, 31: 474-479. 10.1002/hep.510310230.PubMed Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, Giannini C, Monti M, Caini P, Villa GL, Laffi G, Gentilini P: T(14;18) translocation in chronic hepatitis C virus infection. Hepatology. 2000, 31: 474-479. 10.1002/hep.510310230.PubMed
95.
go back to reference Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe J: bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol. 2001, 112: 364-369. 10.1046/j.1365-2141.2001.02573.x.PubMed Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe J: bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol. 2001, 112: 364-369. 10.1046/j.1365-2141.2001.02573.x.PubMed
96.
go back to reference Libra M, Gloghini A, Malaponte G, Gangemi P, De Re V, Cacopardo B, Spandidos DA, Nicoletti F, Stivala F, Zignego AL, Carbone A: Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol. 2008, 49: 170-174. 10.1016/j.jhep.2008.03.031.PubMed Libra M, Gloghini A, Malaponte G, Gangemi P, De Re V, Cacopardo B, Spandidos DA, Nicoletti F, Stivala F, Zignego AL, Carbone A: Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol. 2008, 49: 170-174. 10.1016/j.jhep.2008.03.031.PubMed
97.
go back to reference Giannelli F, Moscarella S, Giannini C, Caini P, Monti M, Gragnani L, Romanelli RG, Solazzo V, Laffi G, La Villa G: Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood. 2003, 102: 1196-1201. 10.1182/blood-2002-05-1537.PubMed Giannelli F, Moscarella S, Giannini C, Caini P, Monti M, Gragnani L, Romanelli RG, Solazzo V, Laffi G, La Villa G: Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood. 2003, 102: 1196-1201. 10.1182/blood-2002-05-1537.PubMed
98.
go back to reference Giannini C, Giannelli F, Zignego A: Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology. 2006, 43: 1166-1167. 10.1002/hep.21132.PubMed Giannini C, Giannelli F, Zignego A: Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology. 2006, 43: 1166-1167. 10.1002/hep.21132.PubMed
99.
go back to reference Giannini C, Petrarca A, Monti M, Arena U, Caini P, Solazzo V, Gragnani L, Milani S, Laffi G, Zignego AL: Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood. 2008, 111: 2943-2945. 10.1182/blood-2007-09-112490.PubMed Giannini C, Petrarca A, Monti M, Arena U, Caini P, Solazzo V, Gragnani L, Milani S, Laffi G, Zignego AL: Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood. 2008, 111: 2943-2945. 10.1182/blood-2007-09-112490.PubMed
100.
go back to reference Kitay-Cohen Y, Amiel A, Hilzenrat N, Buskila D, Ashur Y, Fejgin M, Gaber E, Safadi R, Tur-Kaspa R, Lishner M: Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood. 2000, 96: 2910-2912.PubMed Kitay-Cohen Y, Amiel A, Hilzenrat N, Buskila D, Ashur Y, Fejgin M, Gaber E, Safadi R, Tur-Kaspa R, Lishner M: Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood. 2000, 96: 2910-2912.PubMed
101.
go back to reference Sasso EH, Martinez M, Yarfitz SL, Ghillani P, Musset L, Piette JC, Cacoub P: Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t(14;18). J Immunol. 2004, 173: 3549-3556.PubMed Sasso EH, Martinez M, Yarfitz SL, Ghillani P, Musset L, Piette JC, Cacoub P: Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t(14;18). J Immunol. 2004, 173: 3549-3556.PubMed
102.
go back to reference Sansonno D, Tucci FA, De Re V, Lauletta G, Montrone M, Libra M, Dammacco F: HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology. 2005, 42: 1019-1027. 10.1002/hep.20887.PubMed Sansonno D, Tucci FA, De Re V, Lauletta G, Montrone M, Libra M, Dammacco F: HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology. 2005, 42: 1019-1027. 10.1002/hep.20887.PubMed
103.
go back to reference Samonakis DN, Germani G, Burroughs AK: Immunosuppression and HCV recurrence after liver transplantation. J Hepatol. 2012, 56: 973-983. 10.1016/j.jhep.2011.06.031.PubMed Samonakis DN, Germani G, Burroughs AK: Immunosuppression and HCV recurrence after liver transplantation. J Hepatol. 2012, 56: 973-983. 10.1016/j.jhep.2011.06.031.PubMed
104.
go back to reference Watt K, Veldt B, Charlton M: A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009, 9: 1707-1713. 10.1111/j.1600-6143.2009.02702.x.PubMed Watt K, Veldt B, Charlton M: A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009, 9: 1707-1713. 10.1111/j.1600-6143.2009.02702.x.PubMed
105.
go back to reference Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002, 122: 889-896. 10.1053/gast.2002.32418.PubMed Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002, 122: 889-896. 10.1053/gast.2002.32418.PubMed
106.
go back to reference Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, Manns MP, Wedemeyer H, Pietschmann T: Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010, 138: 1875-1884. 10.1053/j.gastro.2010.02.004.PubMed Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, Manns MP, Wedemeyer H, Pietschmann T: Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010, 138: 1875-1884. 10.1053/j.gastro.2010.02.004.PubMed
107.
go back to reference Fafi-Kremer S, Habersetzer F, Baumert TF: Hepatitis C virus entry and glucocorticosteroids. J Hepatol. 2010, 53: 1148-1150. 10.1016/j.jhep.2010.07.007.PubMed Fafi-Kremer S, Habersetzer F, Baumert TF: Hepatitis C virus entry and glucocorticosteroids. J Hepatol. 2010, 53: 1148-1150. 10.1016/j.jhep.2010.07.007.PubMed
108.
go back to reference Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D: A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011, 17: 1394-1403. 10.1002/lt.22417.PubMed Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D: A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011, 17: 1394-1403. 10.1002/lt.22417.PubMed
109.
go back to reference Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S: Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005, 129: 1031-1041. 10.1053/j.gastro.2005.06.031.PubMed Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S: Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005, 129: 1031-1041. 10.1053/j.gastro.2005.06.031.PubMed
110.
go back to reference Cardenas ME, Zhu D, Heitman J: Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens. 1995, 4: 472-477. 10.1097/00041552-199511000-00002.PubMed Cardenas ME, Zhu D, Heitman J: Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens. 1995, 4: 472-477. 10.1097/00041552-199511000-00002.PubMed
111.
go back to reference Taylor AL, Watson CJ, Bradley JA: Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005, 56: 23-46. 10.1016/j.critrevonc.2005.03.012.PubMed Taylor AL, Watson CJ, Bradley JA: Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005, 56: 23-46. 10.1016/j.critrevonc.2005.03.012.PubMed
112.
go back to reference Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, Montgomery RA, Cameron AM, Maley WR: Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008, 14: 512-525. 10.1002/lt.21396.PubMed Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, Montgomery RA, Cameron AM, Maley WR: Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008, 14: 512-525. 10.1002/lt.21396.PubMed
113.
go back to reference Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, Dusheiko G, Davidson B, Rolles K, Burroughs AK: Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens [see comments]. Gut. 1999, 45: 427-434. 10.1136/gut.45.3.427.PubMedPubMedCentral Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, Dusheiko G, Davidson B, Rolles K, Burroughs AK: Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens [see comments]. Gut. 1999, 45: 427-434. 10.1136/gut.45.3.427.PubMedPubMedCentral
114.
go back to reference Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P: Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol. 1997, 92: 1453-1457.PubMed Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P: Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol. 1997, 92: 1453-1457.PubMed
115.
go back to reference Rostaing L, Chabannier MH, Modesto A, Rouzaud A, Cisterne JM, Tkaczuk J, Durand D: Predicting factors for long-term results of OKT3 therapy in steroid-resistant acute rejection following cadaveric renal transplantation. Transplant Proc. 1998, 30: 1170-1172. 10.1016/S0041-1345(98)00195-X.PubMed Rostaing L, Chabannier MH, Modesto A, Rouzaud A, Cisterne JM, Tkaczuk J, Durand D: Predicting factors for long-term results of OKT3 therapy in steroid-resistant acute rejection following cadaveric renal transplantation. Transplant Proc. 1998, 30: 1170-1172. 10.1016/S0041-1345(98)00195-X.PubMed
116.
go back to reference Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR: Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009, 9: 1406-1413. 10.1111/j.1600-6143.2009.02642.x.PubMed Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR: Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009, 9: 1406-1413. 10.1111/j.1600-6143.2009.02642.x.PubMed
117.
go back to reference Wiesner RH, Sorrell M, Villamil F: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003, 9: S1-9.PubMed Wiesner RH, Sorrell M, Villamil F: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003, 9: S1-9.PubMed
118.
go back to reference Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C: Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J Hepatol. 2006, 45: 127-143. 10.1016/j.jhep.2006.05.001.PubMed Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C: Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J Hepatol. 2006, 45: 127-143. 10.1016/j.jhep.2006.05.001.PubMed
119.
go back to reference Berenguer M: What determines the natural history of recurrent hepatitis C after liver transplantation?. J Hepatol. 2005, 42: 448-456.PubMed Berenguer M: What determines the natural history of recurrent hepatitis C after liver transplantation?. J Hepatol. 2005, 42: 448-456.PubMed
120.
go back to reference Lake JR: The role of immunosuppression in recurrence of hepatitis C. Liver Transpl. 2003, 9: S63-66. 10.1053/jlts.2003.50264.PubMed Lake JR: The role of immunosuppression in recurrence of hepatitis C. Liver Transpl. 2003, 9: S63-66. 10.1053/jlts.2003.50264.PubMed
121.
go back to reference Berenguer M: Recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transpl. 2007, 13: 641-643. 10.1002/lt.21136.PubMed Berenguer M: Recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transpl. 2007, 13: 641-643. 10.1002/lt.21136.PubMed
122.
go back to reference Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, Lopez-Andujar R, Moya A, Pareja E, Montalva E, Yago M: Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation. 2010, 90: 1204-1209. 10.1097/TP.0b013e3181fa93fa.PubMed Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, Lopez-Andujar R, Moya A, Pareja E, Montalva E, Yago M: Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation. 2010, 90: 1204-1209. 10.1097/TP.0b013e3181fa93fa.PubMed
123.
go back to reference Irish WD, Arcona S, Bowers D, Trotter JF: Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant. 2011, 11: 1676-1685. 10.1111/j.1600-6143.2011.03508.x.PubMed Irish WD, Arcona S, Bowers D, Trotter JF: Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant. 2011, 11: 1676-1685. 10.1111/j.1600-6143.2011.03508.x.PubMed
124.
go back to reference Levy G, Grazi GL, Sanjuan F, Wu Y, Muhlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F: 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006, 12: 1464-1472. 10.1002/lt.20802.PubMed Levy G, Grazi GL, Sanjuan F, Wu Y, Muhlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F: 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006, 12: 1464-1472. 10.1002/lt.20802.PubMed
125.
go back to reference Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro J, Kneteman NM: The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol. 2011, 25: 28-34.PubMedPubMedCentral Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro J, Kneteman NM: The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol. 2011, 25: 28-34.PubMedPubMedCentral
126.
go back to reference Lebbe C, Legendre C, Frances C: Kaposi sarcoma in transplantation. Transplant Rev (Orlando). 2008, 22: 252-261. 10.1016/j.trre.2008.05.004. Lebbe C, Legendre C, Frances C: Kaposi sarcoma in transplantation. Transplant Rev (Orlando). 2008, 22: 252-261. 10.1016/j.trre.2008.05.004.
127.
go back to reference Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle J: Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998, 28: 823-830. 10.1002/hep.510280333.PubMed Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle J: Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998, 28: 823-830. 10.1002/hep.510280333.PubMed
128.
go back to reference Trotter JF, Gillespie BW, Terrault NA, Abecassis MM, Merion RM, Brown RS, Olthoff KM, Hayashi PH, Berg CL, Fisher RA, Everhart JE: Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl. 2011, 17: 409-417. 10.1002/lt.22246.PubMedPubMedCentral Trotter JF, Gillespie BW, Terrault NA, Abecassis MM, Merion RM, Brown RS, Olthoff KM, Hayashi PH, Berg CL, Fisher RA, Everhart JE: Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl. 2011, 17: 409-417. 10.1002/lt.22246.PubMedPubMedCentral
129.
go back to reference Berenguer M: Hot topic in hepatitis C virus research: the type of immunosuppression does not matter. Liver Transpl. 2011, 17 (Suppl 3): S24-28.PubMed Berenguer M: Hot topic in hepatitis C virus research: the type of immunosuppression does not matter. Liver Transpl. 2011, 17 (Suppl 3): S24-28.PubMed
130.
go back to reference Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P: Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999, 29: 257-263. 10.1002/hep.510290123.PubMed Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P: Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999, 29: 257-263. 10.1002/hep.510290123.PubMed
131.
go back to reference Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005, 5: 1452-1461. 10.1111/j.1600-6143.2005.00864.x.PubMed Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005, 5: 1452-1461. 10.1111/j.1600-6143.2005.00864.x.PubMed
132.
go back to reference Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S: Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011, 11: 48-55. 10.1016/j.autrev.2011.07.005.PubMed Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S: Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011, 11: 48-55. 10.1016/j.autrev.2011.07.005.PubMed
133.
go back to reference Zaja F, De Vita S, Russo D, Michelutti A, Fanin R, Ferraccioli G, Baccarani M: Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum. 2002, 46: 2252-2254. 10.1002/art.10345. author reply 2254–2255PubMed Zaja F, De Vita S, Russo D, Michelutti A, Fanin R, Ferraccioli G, Baccarani M: Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum. 2002, 46: 2252-2254. 10.1002/art.10345. author reply 2254–2255PubMed
134.
go back to reference Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003, 101: 3827-3834. 10.1182/blood-2002-09-2856.PubMed Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003, 101: 3827-3834. 10.1182/blood-2002-09-2856.PubMed
135.
go back to reference Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003, 101: 3818-3826. 10.1182/blood-2002-10-3162.PubMed Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003, 101: 3818-3826. 10.1182/blood-2002-10-3162.PubMed
136.
go back to reference Petrarca A, Rigacci L, Monti M, Giannini C, Bernardi F, Caini P, Colagrande S, Bosi A, Laffi G, Zignego AL: Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis. 2007, 39 (Suppl 1): S129-133.PubMed Petrarca A, Rigacci L, Monti M, Giannini C, Bernardi F, Caini P, Colagrande S, Bosi A, Laffi G, Zignego AL: Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis. 2007, 39 (Suppl 1): S129-133.PubMed
137.
go back to reference Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM: Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998, 83: 1224-1230. 10.1002/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6.PubMed Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM: Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998, 83: 1224-1230. 10.1002/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6.PubMed
138.
go back to reference Mailliard ME, Capadano ME, Hrnicek MJ, Gilroy RK, Gulizia JM: Outcomes of a patient-to-patient outbreak of genotype 3a hepatitis C. Hepatology. 2009, 50: 361-368. 10.1002/hep.22992.PubMed Mailliard ME, Capadano ME, Hrnicek MJ, Gilroy RK, Gulizia JM: Outcomes of a patient-to-patient outbreak of genotype 3a hepatitis C. Hepatology. 2009, 50: 361-368. 10.1002/hep.22992.PubMed
139.
go back to reference Firpi RJ, Nelson DR: Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008, 22: 117-126. 10.1016/j.blre.2008.02.001.PubMed Firpi RJ, Nelson DR: Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008, 22: 117-126. 10.1016/j.blre.2008.02.001.PubMed
140.
go back to reference Nosotti L, D'Andrea M, Pitidis A, Pimpinelli F, Dessanti ML, Pisani F, Vignally P, Petti MC: Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy. Scand J Infect Dis. 2011, 44: 70-73.PubMed Nosotti L, D'Andrea M, Pitidis A, Pimpinelli F, Dessanti ML, Pisani F, Vignally P, Petti MC: Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy. Scand J Infect Dis. 2011, 44: 70-73.PubMed
141.
go back to reference Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E: Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis. 2011, 44: 49-54.PubMed Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E: Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis. 2011, 44: 49-54.PubMed
142.
go back to reference Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y: Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010, 116: 5119-5125. 10.1182/blood-2010-06-289231.PubMed Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y: Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010, 116: 5119-5125. 10.1182/blood-2010-06-289231.PubMed
143.
go back to reference Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, Rattotti S, Orlandi E, Rumi E, Ferretti V: Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol. 2010, 85: 46-50.PubMed Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, Rattotti S, Orlandi E, Rumi E, Ferretti V: Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol. 2010, 85: 46-50.PubMed
Metadata
Title
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact
Authors
Anna Linda Zignego
Carlo Giannini
Laura Gragnani
Alessia Piluso
Elisa Fognani
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-158

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.